Isaac S. Ashkenazi is a partner in the Litigation practice of Paul Hastings LLP. Mr. Ashkenazi focuses his practice on complex patent litigation primarily in the pharmaceutical, chemistry, and biotechnology fields. He has experience with a broad range of technologies, including pharmaceutical compounds, proteins, polymers, formulations, and chemical and synthetic processes. Mr. Ashkenazi has represented life sciences companies in patent cases involving a wide variety of therapeutics, including oncology drugs, proton pump inhibitors, sleep agents, respiratory agents, antiemetics, and cholesterol lowering and antidiabetic agents.
New York Law Journal Recognizes Paul Hastings Life Sciences IP Litigators as New York Trailblazers
May 20, 2019
Paul Hastings Wins Top Honors at 2019 Managing IP Americas Awards
April 08, 2019
Paul Hastings Wins Hatch-Waxman Litigation Firm of the Year at LMG Life Sciences Awards
September 13, 2018
Five Paul Hastings Lawyers Named Law360 Rising Stars
July 30, 2018
Paul Hastings Named Transatlantic IP Team of the Year by The American Lawyer
June 15, 2018
Paul Hastings Wins Law360 Life Sciences Practice Group of the Year
February 05, 2018
District of New Jersey Prevents Generic Challenger from Using Claim Construction as a Backdoor to Introduce Barred Invalidity Defense
June 16, 2014
Federal Circuit Clarifies That Foreseeability Does Not Preclude the Application of the Doctrine of Equivalents
February 20, 2014
The Federal Circuit Further Clarifies The Obviousness-Type Double Patenting Doctrine For Composition Claims
August 27, 2012
Federal Circuit Signals Reigning in of Janssen and Rasmusson on Enablement/Utility
August 01, 2011
Failure to Launch
April 07, 2011
Federal Circuit Vacates Injunction Against Generic Drug Manufacturer, Determining That A Settlement Agreement Term Is Ambiguous
December 29, 2010
District of New Jersey Resets KUDCos ANDAs Final Approval in Protonix Litigation, Notwithstanding Outstanding Defenses of Teva and Sun
August 19, 2010
Generic Drug Manufacturers Inequitable-Conduct Defenses Dismissed for Failing to Meet Exergens Stringent Pleading Standard
June 08, 2010
Patent Law Reform Bills Introduced in Congress
March 04, 2009
Recognized by Managing IP as the Life Sciences IP Litigation Firm of the Year
Paul Hastings was was recognized by Managing IP at their Americas Awards, which honored individuals and companies behind the most innovative and challenging IP work of the past year, as well as those driving the international IP market.
The firm was recognized as Life Sciences IP Litigation Firm of the Year in the United States.
April 05, 2019
Recognized as the Hatch-Waxman Litigation Firm of the Year by LMG Life Sciences
LMG Life Sciences announced that the firm’s Intellectual Property practice was honored at the LMG Life Sciences Awards as the Hatch-Waxman Litigation Firm of the Year (Branded). The publication cited the firm for wins on behalf of Sunovion Pharmaceuticals, which locked in compound patent protection for Latuda®, the company’s billion-dollar-plus-per-year schizophrenia and bipolar drug, after a judgment of infringement that was affirmed by the Federal Circuit; and for Orexigen Therapeutics after a trial victory where the judge found all three patents-in-suit to be valid and infringed. The firm was also noted for obtaining an unprecedented six walk-away consent judgments in a major pharmaceutical litigation.
The firm and its partners were also shortlisted for:
* Inter-Partes Review Firm of the Year
* Post Grant Proceedings Attorney of the Year: Naveen Modi
* General Patent Litigator of the Year – New York: Bruce Wexler
September 13, 2018
Recognized as a Law360 Rising Star in Life Sciences
Isaac Ashkenazi was recognized by Law360 as a Rising Star in its annual list of lawyers under 40 whose legal accomplishments transcend their age.
July 30, 2018
Recognized as the Transatlantic IP Team of the Year by The American Lawyer
The American Lawyer named Paul Hastings its Transatlantic IP Team of the Year at the Transatlantic Legal Awards. The practice was honored due to Bruce Wexler, Eric Dittmann, and Isaac Ashkenazi leading a team in a major pharmaceutical litigation through fact, expert and Markman phases, and obtaining six walk-away consent judgments.
The awards consider the top legal work between the U.S. and the U.K. and European legal markets, recognizing law firms for “excellence in handling transatlantic matters across the key areas of corporate, finance, and disputes, as well as highlighting law firm innovation, commitment to pro bono, outstanding transatlantic strategy, and in-house leaders.”
June 15, 2018
Recognized as Law360 Practice Group of the Year in Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360. The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product. The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
February 01, 2018
Recognized at the 2016 LMG Life Sciences Awards
Paul Hastings was recognized with multiple LMG Life Sciences Awards. Bruce Wexler was named “General Patent Litigator of the Year – New York” and Naveen Modi was recognized as Post Grant Proceedings Attorney of the Year. The Life Sciences Patent Litigation practice also won awards for two Hatch-Waxman Impact Cases of the Year, including Helsinn Healthcare SA v. Teva Pharmaceuticals USA, a win resolving a long-running patent dispute over Aloxi®, a drug used to treat chemotherapy-induced nausea and vomiting.
The Paul Hastings team representing Helsinn was led by Joseph O’Malley. The firm was also honored for its work on behalf of Eli Lily in Sanofi-Aventis US v. Eli Lilly & Co., where Bruce Wexler led the team representing Eli Lily in litigation regarding the marketing of Basaglar®, its insulin glargine drug product. The case was settled in late 2015, with the press reporting Eli Lilly’s ability to launch the drug.
September 16, 2016
Shortlisted for four LMG Life Sciences Awards for 2016
The Firm was shortlisted in four categories for the LMG Life Sciences Awards. Joseph O’Malley was nominated in the Hatch-Waxman Litigator of the Year – Branded category, Bruce Wexler was nominated in the General Patent Litigator of the Year - New Yorkcategory, Naveen Modi was nominated in the Post Grant Proceedings Attorney of the Year category, and the Firm was nominated in the “Hatch-Waxman Litigation Firm of the Year – Branded” category.
July 27, 2016
Paul Hastings IP Practice Honored in 2016 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM Patent 1000: The World’s Leading Patent Professionals 2016. The guide ranked the firm’s Nationwide, New York, Washington, D.C., and Georgia IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Robin McGrath, Naveen Modi, Joseph O'Malley, Joseph Palys, Preston Ratliff, Samuel Waxman, and Bruce Wexler were recognized as leading lawyers.
May 27, 2016
Managing IP 2016 North America Awards
Naveen Modi was named Outstanding IP Litigator of the Year – PTAB at Managing IP's 2016 North America Awards. Additionally, Paul Hastings was shortlisted in the US Life Sciences IP Litigation Firm of the Year, Patent Contentious Northeast Firm of the Year, and PTAB Firm of the Year categories.
March 18, 2016
Managing Intellectual Property's 2016 IP Stars
Paul Hastings was recognized nationally in Managing Intellectual Property's 2016 IP Stars rankings. The firm was ranked in Tier 2 in the US Bio/Life Sciences category, Tier 2 in the US PTAB litigation (USPTO) category, and Tier 3 in the US Patent Contentious category.
March 02, 2016
Paul Hastings IP Practice Honored in 2015 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM
Patent 1000: The World’s Leading Patent Professionals 2015. The guide ranked the firm’s Nationwide, New York, and Washington, D.C. IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Naveen Modi, Joseph O'Malley, Steven Park, Jeff Randall, Preston Ratliff, Allan Soobert, and Bruce Wexler were recognized as leading lawyers.
June 17, 2015
Managing IP's 2015 IP Stars
Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Chris Kennerly, Naveen Modi, Joseph O'Malley, and Bruce Wexler were named 2015 IP Stars by Managing Intellectual Property magazine. Nationwide, the firm's Intellectual Property practice was ranked in the Bio/Life Sciences, Copyright, and Patent Contentious categories. In New York, the firm was ranked Highly Recommended in the Patent Contentious category, and in California, the firm was ranked Recommended in the Copyright and Patent Contentious categories.
May 15, 2015
Recognized by LMG Life Sciences for Life Sciences IP Litigation
Paul Hastings' Life Sciences Intellectual Property practice received the highest possible ranking in Legal Media Group’s Life Sciences 2014 guide; as it was ranked “Highly Recommended” in the Hatch-Waxman Patent Litigation (Branded) and General Patent Litigation categories. Commentary from the guide singled out Joseph O’Malley and Bruce Wexler as “preeminent litigators in the industry” and pointed out Gerald Flattmann’s "ability to serve as lead counsel in important industry cases." The IP practice was also described as having “outstanding teams both for commercial patent litigation as well as in dealing with infringement suits on the branded Hatch-Waxman front.”
October 09, 2014
Legal Media Group's 2013 LMG Life Science Awards
The firm was nominated as a 2013 LMG Life Science nominee in the “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year” categories.
August 12, 2013
Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010